Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan Road II, Guangzhou, Guangdong 510080, China.
Department of Pediatrics, Nanfang Hospital, Southern Medical University, No. 1838, North Road, Guangzhou Avenue, Guangzhou, Guangdong 510515, China.
Clin Chim Acta. 2020 Jul;506:136-144. doi: 10.1016/j.cca.2020.03.015. Epub 2020 Mar 12.
Nephronophthisis (NPHP) is the most common genetic cause of end-stage renal disease (ESRD) in children. This study was performed to explore the pathogenic gene mutations and clinical and pathological features of Chinese patients with NPHP.
Patients for whom causative mutations were not identified in our previous study, as well as those recruited later, were subjected to whole-exome next-generation sequencing (NGS) or the exome of 63 primary cilia disease genes.
We recruited 55 patients (27 boys and 28 girls) from 48 families, mainly from South China. We subjected 35 patients to NGS. Disease-causing mutations were revealed in seven more families (nine patients) by NGS. In total, disease-causing mutations were identified in 25 patients from 19 families, accounting for 39.6% (19/48) of all families, and novel mutation rate was 77.8% (35/45). NPHP1 and NPHP3 mutations were identified in 14.6% (7/48) and 12.5% (6/48) of all families, respectively. The patient with CEP83 mutations presented with prominent glomerular cysts and glomeruli dysplasia without extrarenal involvement.
A high novel mutation rate was identified, and disease-causing mutations of NPHP3 prevailed in this group of Chinese NPHP patients. This is the second report of a patient with CEP83 mutations.
肾髓质囊性病(NPHP)是儿童终末期肾病(ESRD)最常见的遗传原因。本研究旨在探讨中国 NPHP 患者的致病基因突变及临床病理特征。
对之前研究中未发现致病突变的患者以及后来招募的患者进行全外显子组下一代测序(NGS)或 63 个原发性纤毛疾病基因外显子组测序。
我们从中国南方的 48 个家系中招募了 55 名患者(27 名男孩和 28 名女孩),对 35 名患者进行了 NGS。通过 NGS 在另外 7 个家系(9 名患者)中发现了致病突变。总共在 19 个家系的 25 名患者中发现了致病突变,占所有家系的 39.6%(19/48),新突变率为 77.8%(35/45)。NPHP1 和 NPHP3 突变分别在所有家系中占 14.6%(7/48)和 12.5%(6/48)。CEP83 突变患者表现为明显的肾小球囊肿和肾小球发育不良,无肾外受累。
本研究中国 NPHP 患者中存在较高的新突变率,且 NPHP3 的致病突变占优势。这是第二个报道 CEP83 突变患者的病例。